Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US3596161097
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00DDY1RK9
FULC
Fulcrum Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Fulcrum Therapeutics Inc
ISIN
US3596161097
TICKER
FULC
MIC
XNAS
REUTERS
FULC.OQ
BLOOMBERG
FULC US
Thu, 01.05.2025       Fulcrum Therapeutics
US3596161097

― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ―...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.04.2025       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcru...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 25.02.2025       Fulcrum Therapeutics
US3596161097

― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ―...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum gr...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.11.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2024 financial results will be released on...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.10.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.09.2024       Fulcrum Therapeutics
US3596161097

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (“Fulcrum” or “the Company”) (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.09.2024       Fulcrum Therapeutics
US3596161097

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the inves...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.09.2024       Fulcrum Therapeutics
US3596161097

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (“Fulcrum” or “the Company”) (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 15.09.2024       Fulcrum Therapeutics
US3596161097

NEW YORK-, Sept. 15, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting th...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 13.09.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulc...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.09.2024       Fulcrum Therapeutics
US3596161097

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. (“Fulcrum” or “the Company”) (NASDAQ: FULC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or fail...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.08.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a series of investor meetings...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 23.08.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.08.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heat...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.08.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to four new employees. Fulcru...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 31.07.2024       Fulcrum Therapeutics
US3596161097

― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ―...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 24.07.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its second quarter 2024 financial results will be released on...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.06.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations to be made at the 31st Annual FSHD Society...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.06.2024       Fulcrum Therapeutics
US3596161097

CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at Goldman Sac...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 13.05.2024       Fulcrum Therapeutics
US3596161097

― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ―...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.05.2024       Fulcrum Therapeutics
US3596161097

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ―...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 27, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 27, 2023) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Fulcrum se...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 27, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 26, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 26, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 23.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 23, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 22, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 21, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 21.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 21, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 20, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 19, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360,...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 19, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 16, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 16, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 14, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 14, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 14.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 13, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360,...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.06.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - June 13, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Perio...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 13, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 12, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 8, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.06.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - June 7, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 7, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 7, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.06.2023       Fulcrum Therapeutics
US3596161097

Did you lose money on investments in Fulcrum Therapeutics, Inc.? If so, please visit Fulcrum Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. New York, New York--(Newsf...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 6, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Fulcrum Therapeutics
Technical Analysis Termsheets Terminal
Permalink